|Mr. Gregory West CA||CEO & Company Sec.||429.71k||N/A||N/A|
|Dr. David A. Suhy B.Sc., Ph.D.||Chief Scientific Officer||360.29k||N/A||N/A|
|Mr. Bryan Dulhunty||Chief Financial Officer||N/A||N/A||N/A|
|Annabel Murphy||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Dr. Michael Graham BSc (Hons), Ph.D.||Head of Discovery and Founding Scientist||N/A||N/A||N/A|
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.
Benitec Biopharma Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.